Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Plasmodium Immunotherapy for Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03375983
Recruitment Status : Recruiting
First Posted : December 18, 2017
Last Update Posted : January 22, 2019
Sponsor:
Information provided by (Responsible Party):
CAS Lamvac Biotech Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.

Condition or disease Intervention/treatment Phase
Advanced Cancers Biological: Blood-stage infection of P.vivax Phase 1 Phase 2

Detailed Description:
This study is to enroll 20 patients. Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites and be observed for the exact infection time, parasitemia condition and infection course; principal clinical symptoms such as fever; gastrointestinal reaction; peripheral blood parameters;heart, liver and kidney function; changes in lung function, and dynamic changes in the function of peripheral immune cells. Moreover, the tolerance of patients to Plasmodium infection and changes in tumor-related parameters will be observed preliminarily.The duration of the planned treatment of each subject is 3-6 months. Since the successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples, the time of the treatment course is based on the presence of peripheral parasitemia. After 3-6 months, parasitemia will be terminated by antimalarial drugs for terminating the treatment of Plasmodium immunotherapy ( the immunological treatment effect may persist after the termination of Plasmodium infection).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study of Plasmodium Immunotherapy for Advanced Cancers
Actual Study Start Date : November 23, 2017
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : July 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Blood-stage infection of P.vivax
This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
Biological: Blood-stage infection of P.vivax
The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0 [ Time Frame: 2 years ]
    Adverse events will be evaluated according to NCI CTCAE 4.0, and the incidence of adverse events will be calculated.


Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: 2 years ]
    Progression free survival (PFS): Starting from treatment until the disease progression is first found or the time of any cause of death (disease progression refers to tumor growth, or metastasis of primary tumor, or discovery of new lesions).

  2. Overall survival [ Time Frame: 2 years ]
    The time starting from the treatment to death of whatever causes (when subjects have lost for follow-up before death, the last follow-up time will be calculated as the time of death).

  3. Tumor marker level [ Time Frame: 2 years ]
    The patient's sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study.

  4. Objective response rate (ORR) [ Time Frame: 2 years ]
    The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time.

  5. Quality of life [ Time Frame: 2 years ]
    Patients are regularly filled with QLQ-C30 (cancer patient quality of life scale) to assess the quality of life of the patients.

  6. 1 year of survival rate [ Time Frame: 2 years ]
    The number of cancer cases remaining after 1 year of treatment / the total number of cancer cases treated * 100%.

  7. 2 year of survival rate [ Time Frame: 2 years ]
    The number of cancer cases remaining after 2 years of treatment / the total number of cancer cases treated * 100%.

  8. Immunological index [ Time Frame: 2 years ]
    Detection of absolute number of immune cells(such as CD3+CD4+、CD3+CD8+ and so on )in peripheral blood by flow cytometry.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-70 years of age, male or female.
  • Patients with advanced cancer confirmed by histopathology and imaging; and imaging lesions of the tumor are clear and measurable, including but not limited to colon cancer, breast cancer, liver cancer, lung cancer, gastric cancer,sarcoma and other solid tumors (except for nasopharyngeal carcinoma, lymphatic cancer, cervical cancer and melanoma).
  • The time interval of the termination of chemotherapy (including interventional chemotherapy) or radiotherapy is at least 3 months for patients who had received chemotherapy (including interventional chemotherapy) or radiotherapy; at least 5 half-life for patients who had received targeted drug therapy (the half-life of targeted drug is according to the drug instructions);
  • All the patients who have not received surgery, radiotherapy, chemotherapy or targeted drug therapy and refuse to accept the above treatments must meet all the remaining requirements that listed in the inclusion criteria;
  • ECGO score of 0 or 1;
  • Expected survival ≥ 6 months;
  • PLT ≥100× 10^9/L, NE ≥ 1.5 × 10^9/L, and HGB ≥ 100 g/L; no significant morphological abnormalities of red blood cells, or anemia (iron deficiency anemia, autoimmune hemolytic anemia, thalassemia, etc.);
  • The peripheral blood count of immune cells is close to normal or normal, the immune function test result is close to or at the level of normal population, and the function of heart, lung, liver and kidney are basically normal (the liver function classification of Child-push is A or B, Cr≤1.5×ULN);
  • Patient compliance meets the need for follow-up;
  • The subjects are able to understand and sign informed consent.

Exclusion Criteria:

  • Patients with severe hemoglobin disease or severe G6PD deficiency;
  • Patients with splenectomy or splenomegaly;
  • Patients with drug addiction or alcohol dependence;
  • With the following diseases or conditions: newly diagnosed with CNS metastasis ( excluding that the tumor lesions of the CNS has disappeared after treatment) and serious or uncontrolled systemic disease or any unstable systemic diseases (including but not limited to active infection, grade three hypertension, unstable angina, congestive heart failure, class III or IV heart disease, severe arrhythmia, liver and kidney dysfunction or metabolic disease), a clear history of neurological or psychiatric disorders, etc;
  • Accept any other anti-tumor treatment at the same time;
  • Patients with significantly lower immune function than those in the normal population;
  • Lung function is seriously damaged, the MNW <39% or can't get out of bed, still feel short of breath when resting;
  • Rough cough, dyspnea, without normal diet or difficult to cooperate;
  • Poor body condition, the researchers assess that the patients can't tolerate the immune therapy;
  • Pregnant or lactating women;
  • Women of childbearing age with positive result for pregnancy tests;
  • Any condition that makes the subject ineligible to participate (in the opinion of the investigator).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03375983


Contacts
Layout table for location contacts
Contact: Li Qin, M.D 0086-18802043960 njlf@cas-lamvac.com
Contact: Suyi Zhang, M.D 0086-20-82258805 zhang_suyi@cas-lamvac.com

Locations
Layout table for location information
China, Guangdong
Guangzhou Fuda Tumor Hospital Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Weibing Zhu, M.D.    86 20 38993978    fuda2@fudahospital.com   
Sponsors and Collaborators
CAS Lamvac Biotech Co., Ltd.
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: CAS Lamvac Biotech Co., Ltd.
ClinicalTrials.gov Identifier: NCT03375983    
Other Study ID Numbers: ZKLH-003
First Posted: December 18, 2017    Key Record Dates
Last Update Posted: January 22, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CAS Lamvac Biotech Co., Ltd.:
Advanced cancer
Plasmodium immunotherapy
Plasmodiun vivax
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Neoplasms
Protozoan Infections
Parasitic Diseases